CCL2 and cancer: Cancer generally establishes an immune-tolerant environment in which it thrives [1], and this may be key to the observations described by Bonapace et al. Withdrawing CCL2-neutralisation in a tolerogenic environment may favour different outcomes to withdrawing treatment during an immunogenic period.